Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834152 | 0.82 | HDAC1 (0.50) | POLBRAB9AMAPTNPC1HDAC1 | |
| SCHEMBL5149849 | 0.82 | MAPT (0.57) | POLBRAB9AMAPTNPC1HDAC1 | |
| Bromide SCHEMBL21382416 | 0.81 | MAPT (0.60) | POLBRAB9AMAPTNPC1HDAC1 | |
| SCHEMBL12206192 | 0.79 | MEN1 (0.50) | RAB9ANPC1GAAALDH1A1 | |
| SCHEMBL4000661 | 0.78 | LMNA (0.61) | RAB9AMAPTNPC1 | |
| SCHEMBL21382353 | 0.77 | RAB9A (0.64) | RAB9AMAPTNPC1 | |
| SCHEMBL4831350 | 0.77 | HDAC1 (0.50) | POLBRAB9AMAPTNPC1HDAC1 | |
| SCHEMBL6498881 | 0.76 | MAPT (0.49) | RAB9AMAPTNPC1HDAC1HDAC6 | |
| SCHEMBL6489114 | 0.76 | SMN1; SMN2 (0.51) | RAB9AMAPTGAA | |
| SCHEMBL4834106 | 0.76 | ALDH1A1 (0.50) | POLBRAB9AMAPTNPC1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287438-A1 | Agent for preventing or treating neuropathy | MOMOSE YU | 2008-11-20 | — | — | US | disclosed |
| US-7423159-B2 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-09 | — | — | US | disclosed |
| CN-1731994-A | Prophylactic and therapeutic agent for neuropathy | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-02-08 | — | — | CN | disclosed |
| US-20060004069-A1 | Agent for preventing or treating neuropathy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1556032-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | Takeda Pharmaceutical Company Limited (JP) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039365-A1 | AGENT FOR PREVENTING OR TREATING NEUROPATHY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004069-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | POLB 3700/4885RAB9A 4059/4885MAPT 3203/4885 |
| US-20080287438-A1 | Agent for preventing or treating neuropathy | NR2C2, NR0B2, NR2E1 | POLB 3700/4885RAB9A 4059/4885MAPT 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.